source
- STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugsBristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.STAT · 2mo ago↗ source
- Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCLRituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.onclive · 2mo ago↗ source
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive